Overall, these preclinical laboratory research findings demonstrate that bi-directional crosstalk between the ER and HER2 pathways in breast cancer may lead to the activation of alternative “escape” survival pathways through ER signaling and, eventually, treatment resistance and tumor growth. The gene discussed is ERBB2; the disease is breast carcinoma.